Drug-induced liver damage -- a three-year study of patients from one gastroenterological department.
BACKGROUND
The aim of our study was to analyze drug-induced liver disease over a 3-year period in one gastroenterological department.


METHODS
International consensus standard definitions and criteria for assessing causality of adverse drug reactions were applied to all patients with abnormal hepatic test results.


RESULTS
Drugs were implicated in hepatic injury in 14 patients (8 females) in whom causal relationship between drug and liver disease was definite or highly probable. The drugs responsible were amoxicillin with clavulanic acid (3 cases), fluvastatin and pravastatin (3 cases), antituberculous drugs (2 cases), estrogens, roxithromycin, asacol, satolol, enalapril and thiamazol. A total of 78.6% (11 cases) were classified as hepatocellular or mixed hepatitis, while cholestatic injury was found in 21.4% (3 cases). There were no lethal or severe (prothrombin < 50%) hepatic drug reactions. In 13 patients the course of liver disease after withdrawal of the offensive drug was either acute or protracted, while in one patient there was chronic cholestasis (>3 years) resulting from injury to interlobular bile ducts by amoxicllin with clavulanic acid.


CONCLUSIONS
A thorough history of drug intake should be taken in all patients presenting with abnormal hepatic test results. Amoxicillin & clavulanic acid, cholesterol-lowering and antituberculin drugs were the most frequent hepatotoxic factors in our patients. In a majority of cases the liver injury was not severe, and resolved after prompt withdrawal of the responsible drug.
Hartleb
Marek
M
Department of Gastroenterology, Silesian Medical University, Katowice, Poland.
Biernat
Lukasz
L
Kochel
Anna
A
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000924:Anticholesteremic Agents / Q000009:adverse effects; D000995:Antitubercular Agents / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology* / Q000209:etiology; D015897:Comorbidity; D004656:Enalapril / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects; D005234:Fatty Liver / Q000453:epidemiology / Q000209:etiology; D005260:Female; D006801:Humans; D008107:Liver Diseases / Q000453:epidemiology; D008297:Male; D019804:Mesalamine / Q000009:adverse effects; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000924:Anticholesteremic Agents; D000995:Antitubercular Agents; D004967:Estrogens; D019804:Mesalamine; D004656:Enalapril